Bryn Mawr Communications public
[search 0]

Download the App!

show episodes
 
Loading …
show series
 
The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, si…
 
In this special Thanksgiving episode of Ophthalmology Off the Grid, host Blake Williamson, MD, MPH, invites his colleagues to join him in expressing their gratitude. Hear from Dr. Williamson; Richard L. Lindstrom, MD; Evan Schoenberg, MD; Iqbal Ike K. Ahmed, MD, FRCSC; and Zaina Al-Mohtaseb, MD, on what has them feeling thankful in these particular…
 
Retinal arteriolar macroaneurysm (RAM) usually regresses spontaneously, but can lead to irreversible vision loss if regression does not occur. Could anti-VEGF therapy be an option for these patients? J. Fernando Arevalo, MD, PhD, joins NRR to discuss data from a study that asked that question. He presented the data at this year’s AAO Annual Meeting…
 
In this episode of the Survive & Thrive series, Gary Wörtz, MD, is joined by Nandini Venkateswaran, MD; Dagny Zhu, MD; and guest Preeya Gupta, MD, to talk about one of the big decisions faced by young ophthalmologists: private practice or academia? They weigh the pros and cons of each career path and share their own experiences in navigating this c…
 
The burden of anti-VEGF therapy is particularly high in DME patients, many of whom are young, in the workforce, and unable to easily maintain monthly therapy. Could the antibody biopolymer conjugate KSI-301 (Kodiak Sciences) alleviate that burden while maintaining the outcomes experienced with anti-VEGF therapy? Arshad M. Khanani, MD, MA, shares th…
 
Arshad M. Khanani, MD, MA, leads a roundtable consisting of Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA, as they discuss the art of drug choice in wet AMD therapy. The panel discusses how and why they switch therapy in challenging wet AMD cases and reviews how the COVID-19 pandemic has factored into thei…
 
In episode 2 of the NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data,” Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleratio…
 
This NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” continues as Dr. Khanani and the roundtable participants Drs. Fuller, London, and Weng review the wet AMD pipeline with a focus on anti-Ang-2 therapy (faricimab, Roche/Genentech) and gene therapy (RGX-314, RegenxBio and ADVM-022, Adverum Biotechnologies). After the break, Dr.…
 
NRR’s miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. K…
 
New Retina Radio’s John Kitchens, MD, and Jorge Fortun, MD, introduce the premier episode of New Retina Radio Journal Club, a new series dedicated to reviewing the latest papers and how they relate to day to day clinical practice. In this episode, Dr. Fortun is joined by Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, to discuss …
 
In this podcast, Prof. Bart Leroy (Belgium), Prof. Isabelle Audo (France) and Prof. Robert Maclaren (UK) discuss the management of patients with inherited retinal diseases (IRDs), from the initial identification of a patient with an IRD and referral to specialist center, through to the confirmation of a diagnosis using genotyping and the long-term …
 
In this podcast of the Survive & Thrive series, Gary Wörtz, MD, is joined by Cherie Fathy, MD; Nandini Venkateswaran, MD; David Felsted, DO; Dagny Zhu, MD; and guest Uday Devgan, MD, FACS, to talk about performing surgery alone for the first time. Drs. Venkateswaran and Felsted share their recent experiences as first-time solo surgeons, and the oth…
 
Arming patients with knowledge is key to fighting any disease. What happens when a confluence of factors create a breeding ground for an uneducated patient population? John W. Kitchens, MD (United States), is joined by Patricio Schlottmann, MD (Argentina), Nicole Eter, MD (Germany), and Adnan Tufail, MBBS, MD, FRCOphth (United Kingdom) to review ta…
 
The COVID-19 pandemic accelerated the use of telemedicine. How has this held up in retina now that we’ve had more than 6 months of experience under our belts? New Retina Radio host John Kitchens, MD, invites Judy E. Kim, MD; Byron Ladd, MD; and Carl D. Regillo, MD, to review how their practices have used (or not used) telemedicine during the pandem…
 
Telemedicine has been put to the test during the COVID-19 pandemic. How is it holding up—and just how effective will it be going forward? John W. Kitchens, MD (United States), is joined by Francesco Boscia, MD (Italy); David Steel, MBBS, FRCOphth (United Kingdom); and Ramin Tadayoni, MD, PhD (France), to discuss how much telemedicine has delivered …
 
The internal regulations governing academic institutions were tested during the COVID-19 surges of spring and summer. As we move into autumn, how effective have they been—and are any worth revisiting? New Retina Radio host John Kitchens, MD, reviews this topic with Dilraj Grewal, MD, from the Duke Eye Center; Adrienne Scott, MD, from the Wilmer Eye…
 
Cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, invite cornea specialist Ed Holland, MD, of the Cincinnati Eye Institute to discuss his career-long passion for treating patients with limbal stem cell deficiency. Dr. Holland shares how this passion led to the development of his Cincinnati Protocol and the creation of the Holland Foundation fo…
 
In this webcast of the Survive & Thrive series, moderators Gary Wörtz, MD, and Lisa Nijm, MD, JD, are joined by Cherie Fathy, MD; Nandini Venkateswaran, MD; David Felsted, DO; and Ashley Brissette, MD, MSc, FRCSC, for a conversation about gender equality in ophthalmology. They touch on the barriers faced by women in ophthalmology, the importance of…
 
The disruptions to clinical and surgical workflows during the COVID-19 crisis are obvious. Less apparent are the downstream effects of adjustments to educational experiences. New Retina Radio host John Kitchens, MD, invites three leaders in academic retina—Sophie Bakri, MD, of the Mayo Clinic; Julia Haller, MD, of Wills Eye Hospital; and R.V. Paul …
 
Approaches to treating retinitis pigmentosa have included prosthetic devices and gene therapy. What if there was an approach that could treat the nearly 2 million worldwide patients with disease? Anthony Joseph, MD, discusses jCell technology, which may work independently of a patient’s genetic subtype to promote photoreceptor survival in retinitis…
 
A COVID-19 resurgence seems increasingly likely as autumn and winter approach the United States, forcing people indoors and increasing transmission risk. What can retina clinicians learn from the spring and summers waves of COVID-19 infections that could be applied to the cooler months of 2020? John W. Kitchens, MD, invites Steve Charles, MD; Amy S…
 
Retina’s ability to adjust to a new environment should be commended. Which of the technologies introduced during the COVID-19 era are stopgaps and which will be a permanent part of the treatment landscape? John W. Kitchens, MD (United States), is joined by María H. Berrocal, MD (United States); Jean-Francois Korobelnik, MD, PhD (France); and Manish…
 
Treat-and-extend therapy is a common tactic employed by retina specialists for treating wet AMD patients. What new data will grow the body of information retina specialists already draw on when making decisions about treatment regimen? Michael Singer, MD, shares details from a retrospective review of patient data over a 2-year period during which t…
 
In this episode, cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, are joined by ophthalmology’s favorite comedian, Dr. Glaucomflecken. Dr. G talks about how comedy started as his creative outlet and led to him becoming the comedic voice of medicine on Twitter. He also shares how he has used humor to help him cope with personal adversity.…
 
In the midst of the COVID-19 pandemic, medicine cannot forget about the raging opioid epidemic taking place in the United States. What role to retina specialists play in fueling the opioid crisis, and how has their behavior changed for the better over time? Yoshihiro Yonekawa, MD, shares his research about opioid prescribing rates among retina spec…
 
The phase 2 LADDER study showed the Port Delivery System for ranibizumab was worthy of a phase 3 trial. Was the device able to deliver a continuous dose of therapy that was similar to what you’d find in monthly injection patients? Dilsher Dhoot, MD, reviews the pharmacokinetic data that researchers used to determine the rate of drug release and the…
 
Protocols for clinical and surgical settings have been altered in the COVID-19 era. Which of those protocols are temporary, and which protocols will be a permanent part of practice? To answer this question, New Retina Radio host John W. Kitchens, MD, invites María Ana Castellanos-Martinez, MD (Mexico) and Matteo Forlini, MD (Italy) for a roundtable…
 
Conferences are an essential dynamic to the retina ecosystem that have been disrupted during the COVID-19 crisis. How will the field advance without in-person meetings? New Retina Radio host John W. Kitchens, MD, invites EURETINA General Secretary Anat Loewenstein, MD, and ASRS President Timothy G. Murray, MD, MBA, to discuss the future of in-perso…
 
Cohost Blake Williamson, MD, MPH, invites Raymond Stein, MD, from Bochner Eye Institute in Toronto for a conversation about the PanOptix, a presbyopia-correcting IOL that was first approved by the FDA last year. Dr. Stein draws on his extensive experience and shares surgical pearls for US-based surgeons who are acclimating to this new technology.…
 
Safe and effective long-duration therapy in wet AMD treatment could be the solution to increasing patient adherence. Are we on the brink of a major breakthrough? Carl Danzig, MD, reviews the phase 2 STAIRWAY study, which evaluated the safety and efficacy of faricimab (Genentech/Roche) for the treatment of wet AMD, and previews the coming phase 3 tr…
 
Dry AMD research was a hot topic at this year's ARVO annual meeting. Could ethically sourced stem cells from human embryos provide a solution to this challenging disease? Chris Riemann, MD, shared data from an early phase trial that sought to understand the safety of RPE cells surgically implanted below the retina.…
 
Dry AMD research was a hot topic at this year's ARVO annual meeting. Could ethically sourced stem cells from human embryos provide a solution to this challenging disease? Chris Riemann, MD, shared data from an early phase trial that sought to understand the safety of RPE cells surgically implanted below the retina.…
 
Learn how to preserve and grow your contact lens patient base with advice from practice owner Dana Salgado, OD (1:57). James Deom, OD, MPH, FAAO, offers scleral lens troubleshooting tips (7:45), and Mile Brujic, OD, FAAO, describes how his practice changed over the course of roughly 30 days due to the coronavirus (12:03), while Nicole Harris, OD, s…
 
The ARVO Board of Trustees had only a few weeks to turn their massive, in-person meeting into a virtual symposium that highlighted the year's biggest advancements in ophthalmology research. Iris Rush, the Executive Director of ARVO, spoke to New Retina Radio about the experience, and spelled out what they learned that can be applied to future ARVO …
 
The ARVO Board of Trustees had only a few weeks to turn their massive, in-person meeting into a virtual symposium that highlighted the year's biggest advancements in ophthalmology research. Iris Rush, the Executive Director of ARVO, spoke to New Retina Radio about the experience, and spelled out what they learned that can be applied to future ARVO …
 
Blake K. Williamson, MD, MPH, MS, shares his experience getting LASIK after years of performing refractive surgery on his patients. Dr. Williamson's father, Charles Williamson, MD, performed the surgery using the STAR S4 IR® Excimer Laser System with iDESIGN® Refractive Studio from Johnson & Johnson Vision. Dr. Blake Williamson compares how his exp…
 
In-person retina conferences are halted, but the flow of data isn't. In this episode of New Retina Radio, Jennifer Lim, MD, breaks down 100-week data from the PANORAMA trial, which she shared at the ARVO virtual meeting. Dr. Lim's presentation may help retina doctors make informed treatment decisions about long-term therapy for nonproliferative dia…
 
In-person retina conferences are halted, but the flow of data isn't. In this episode of New Retina Radio, Jennifer Lim, MD, breaks down 100-week data from the PANORAMA trial, which she shared at the ARVO virtual meeting. Dr. Lim's presentation may help retina doctors make informed treatment decisions about long-term therapy for nonproliferative dia…
 
Loading …

Quick Reference Guide

Copyright 2020 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login